Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan’s Oral CGRP Inhibitor Ubrelvy Approved For Migraine Attacks

Executive Summary

With a US FDA endorsement, the drug – soon to join AbbVie’s portfolio under the companies’ $63bn merger – is the first oral option in its class and the first CGRP inhibitor approved to stop a migraine when it strikes.

You may also be interested in...



Market Snapshot: Three Acute Migraine Launches Are First In Over 20 Years

Lilly, Allergan and Biohaven plan to launch oral drugs for on-demand treatment of migraine attacks in the first quarter, hoping to harness a large market where new preventive therapies are already competing for patients.

Market Snapshot: Migraine Prevention Therapies’ Slow Road To Blockbuster Status

Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.

Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019

The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC141394

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel